Stephanie Monaghan O'Brien

This profile gathers the share dealings of Stephanie Monaghan O'Brien in Apellis Pharmaceuticals, Inc., where the filings describe the role as senior executive. The record holds 7 filings, for trades running from 1 January 2022 to 14 May 2026.

The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

Most recently, on 14 May 2026, the filings show a transaction in Apellis Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.